UNASSIGNED: The incidence and prognostic role of @entity517 and @entity588 rearrangements in mature @entity1892 have been extensively studied, except the infrequent @entity1073 ( @entity1073 ). Here, we analyzed the @entity517 and @entity588 abnormalities and other cytogenetic aberrations by fluorescence in situ hybridization (FISH) in 50 @entity1073 @entity1 with bone marrow involvement. Eighteen @entity1 (36.0%) had @entity517 gains and/or amplifications, and twelve @entity1 (24.0%) had @entity588 gains and/or amplifications. Among the 18 @entity1 with @entity517 abnormality, four had simultaneous @entity517 translocations, but no @entity588 translocation was detected among @entity1 with @entity588 abnormality. Only two @entity1 (4.0%) had both @entity517 and @entity588 abnormalities. The @entity1 with a @entity517 abnormality had a significantly higher @entity5 burden, a higher percentage of medium/high risk MIPI group and genomic instability compared to those without this abnormality. However, no significant difference was observed between @entity1 with or without a @entity588 abnormality in terms of clinical and cytogenetic factors. @entity1 with a @entity517 abnormality had poorer progress-free survival (PFS) (9.0 vs. 48.0 months, p = .000) and @entity1349 ( @entity1349 ) (12.0 vs. 94.5 months, p = .000), but the presence of a @entity588 abnormality did not significantly influence either PFS or @entity1349 . In multivariate analysis, the @entity517 abnormality was the independent adverse factor for both PFS and @entity1349 , and intensive chemotherapy did not improve the outcome of these @entity1 . Thus, the presence of a @entity517 but not @entity588 abnormality predicted the poor survival of @entity1073 @entity1 , and a new treatment strategy should be developed for these @entity1 .

High incidence of @entity517 and @entity588 abnormalities in XXXX , although only @entity517 abnormality predicts poor survival.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity588 :: ('596', 'Gene') :: ['BCL2'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity517 :: ('4609', 'Gene') :: ['MYC'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['B-cell lymphomas'] @entity1073 :: ('MESH:D020522', 'Disease') :: ['mantle cell lymphoma', 'MCL'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1073 :: (MESH:D020522,Disease) :: ['mantle cell lymphoma']
